id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2020-E-2361-0009,FDA,FDA-2020-E-2361,Letter from FDA CDER to U S Patent and Trademark Office,Other,Letter(s),2023-07-13T04:00:00Z,2023,7,2023-07-13T04:00:00Z,,2023-07-13T16:49:08Z,,0,0,0900006485ca2153
FDA-2020-E-2361-0008,FDA,FDA-2020-E-2361,Determination of Regulatory Review Period for Purposes of Patent Extension; ENSPRYNG; Correction,Notice,Correction,2023-05-24T04:00:00Z,2023,5,2023-05-24T04:00:00Z,,2023-05-24T13:14:34Z,2023-10979,0,0,0900006485a47c54
FDA-2020-E-2361-0007,FDA,FDA-2020-E-2361,"Response Letter from FDA CDER to Fish & Richardson, P.C.",Other,Letter(s),2023-05-16T04:00:00Z,2023,5,2023-05-16T04:00:00Z,,2023-05-16T14:26:43Z,,0,0,0900006485a10c08